FACS

Axena Health Commends New Study Showing the Leva System’s Long-term Treatment Efficacy for Female Urinary Incontinence

Retrieved on: 
Tuesday, January 23, 2024
Women, Seniors, Physical Therapy, Health, FDA, Medical Devices, Health Technology, Consumer, Woman, Patient, Reproductive biology, Associate, MD, The Green Journal, Overactive bladder, Female, RCT, Harvard Medical School, Manager, FACS, PFMT, Urinary incontinence, University, Medicine, Quality of life, Risk, Incontinence, Food, Journal, FACOG, Storey, UI, Hospital, ACOG, Massachusetts General Hospital, American College, Birth control

Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, announced today that leading pelvic health researchers have published a new study demonstrating the Leva® Pelvic Health System’s long-term treatment efficacy for female urinary incontinence (UI).

Key Points: 
  • Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, announced today that leading pelvic health researchers have published a new study demonstrating the Leva® Pelvic Health System’s long-term treatment efficacy for female urinary incontinence (UI).
  • “Two years of data showing that UI symptom relief endures following eight weeks of guided-PFMT offers compelling evidence that women can access first-line, conservative treatment successfully.
  • “This newest published study offers powerful evidence that women can access first-line treatment successfully, and that this treatment has a lasting effect.
  • “Pelvic floor muscle training is globally recommended first-line treatment for urinary incontinence,” said Eileen Maus, CEO of Axena Health.

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body

Retrieved on: 
Monday, January 22, 2024
General Health, Health, Surgery, Other Health, Patient, MD, Plastic, Face, Neck, FACS, Systematic review, Abdomen, Food, Plasma, Human, FDA, Buttocks, Medical imaging

Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the publication of a peer-reviewed article in the Aesthetic Surgery Journal Open Forum, which evaluated the use of Renuvion for contracting subcutaneous soft tissue following liposuction in multiple areas of the body.

Key Points: 
  • Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the publication of a peer-reviewed article in the Aesthetic Surgery Journal Open Forum, which evaluated the use of Renuvion for contracting subcutaneous soft tissue following liposuction in multiple areas of the body.
  • “We are excited to see the publication of this real-world 483-patient analysis, demonstrating Renuvion’s impressive safety when used after liposuction, which is now the most commonly performed cosmetic procedure in the world.,” said Charlie Goodwin, President and Chief Executive Officer of Apyx Medical.
  • Additionally, they concluded that the risks associated with the use of Renuvion for subcutaneous soft tissue contraction following liposuction do not differ significantly by body area.
  • A digital version of the clinical publication is available via the following link: https://doi.org/10.1093/asjof/ojad112

MAX Surgical Specialty Management LLC (MAX) Enters Two New States with Strategic Partnerships Setting the Tone for Strong Growth in 2024

Retrieved on: 
Wednesday, January 24, 2024
OMS, VOSA, Orthognathic surgery, Anesthesia, Sleep apnea, FACS, Associate, MAX, Surgeon, Education, Dentistry

We are the changemakers of surgeon-led OMS platforms and it's great to see these developments in real time."

Key Points: 
  • We are the changemakers of surgeon-led OMS platforms and it's great to see these developments in real time."
  • In New York, MAX is excited to have partnered with New York Oral, Maxillofacial, and Implant Surgery (NYOMIS) with locations in Scarsdale and Mt.
  • These surgeons and their entire teams demonstrate an unwavering commitment to clinical excellence, patient-centric care, education, and unparalleled outcomes.
  • These new partnerships for MAX in New York and Vermont are significant strides towards achieving their vision of redefining the space in which they operate.

Fast Forward Thinking: 40 Rules for Entrepreneurs and Investors in Medical, Science, and Biotech

Retrieved on: 
Friday, January 19, 2024
Knowledge, Empowerment, Biotechnology, MD, FRCS, FACS, AAPL, Investment, Future, Doctor of Philosophy, Entrepreneurship, Physician, Cryptocurrency

WASHINGTON, Jan. 19, 2024 /PRNewswire/ -- Is your "cutting edge" entrepreneurial idea sharp enough? A new book written by a neurosurgeon turned venture capitalist offers guidance from someone who has been there and done that. Fast Forward Thinking: 40 Rules for Entrepreneurs and Investors in Medical, Science, and Biotech is published by the American Association for Physician Leadership (AAPL).

Key Points: 
  • A new book written by a neurosurgeon turned venture capitalist offers guidance from someone who has been there and done that.
  • Fast Forward Thinking: 40 Rules for Entrepreneurs and Investors in Medical, Science, and Biotech is published by the American Association for Physician Leadership (AAPL).
  • Fast Forward Thinking offers a unique blend of science, venture capital, and the art of predicting future trends, making it a must-read for anyone interested in healthcare science-driven ventures.
  • "Our industry, and society in general, is better for those intrepid physicians who have literally invented better means of delivering healthcare."

RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS

Retrieved on: 
Tuesday, January 16, 2024
Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Therapy, Vance DeGeneres, FACS, University, AMD

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results showing retinal structure improvements with RG6501( OpRegen ) from a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) in geographic atrophy (GA) secondary to advanced age-related macular degeneration (AMD), will be presented at the 2024 Angiogenesis, Exudation, and Degeneration Meeting .

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results showing retinal structure improvements with RG6501( OpRegen ) from a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) in geographic atrophy (GA) secondary to advanced age-related macular degeneration (AMD), will be presented at the 2024 Angiogenesis, Exudation, and Degeneration Meeting .
  • The virtual meeting will be held February 3, 2024, and is sponsored by the University of Miami Health System Bascom Palmer Eye Institute .
  • The presentation, “Retinal Structure Improvements with OpRegen RPE Cell Therapy in a Phase I/IIa Study in Geographic Atrophy,” will be presented by Allen Ho , MD, FACS, FASRS, Co-Director, Wills Eye Retina Service and Director, Retina Research, Wills Eye Hospital on behalf of Roche and Genentech , a member of the Roche Group.

Providence Health Plan Names New Chief Medical Officer

Retrieved on: 
Tuesday, January 16, 2024
Health, Providence Health & Services, Medical director, The Mission, FACS, Mission, University, PHP, CMO

PORTLAND, Ore., Jan. 16, 2024 /PRNewswire/ -- Providence Health Plan (PHP) is pleased to announce Laurel Soot, MD, FACS, has been named Chief Medical Officer (CMO). Dr. Soot has served in the interim CMO role since November 2023, demonstrating exceptional leadership that is crucial at this pivotal time for the organization. Soot assumed the role of CMO on January 14.

Key Points: 
  • PORTLAND, Ore., Jan. 16, 2024 /PRNewswire/ -- Providence Health Plan (PHP) is pleased to announce Laurel Soot, MD, FACS, has been named Chief Medical Officer (CMO).
  • Dr. Soot earned her medical degree from the University of Washington, Seattle, and completed her surgical residency at Oregon Health Sciences University in Portland.
  • She currently chairs the PHP Medical Policy Committee and is a member of the Oregon Health Leadership Council Evidence-Based Best Practice Committee.
  • "Providence Health Plan is a mission-driven organization that prioritizes individualized member care and values its employees' well-being," Dr. Soot said.

The Inner Circle Acknowledges, Divyakant B. Gandhi, MBBS, FRCS, FACS as a Distinguished Cardiothoracic Surgeon

Retrieved on: 
Monday, January 15, 2024
Student, Atrial fibrillation, Patient, University, Research, Medical college, FRCS, Health, Multimedia, Heart, Inner circle, Cardiothoracic surgery, Circulatory system, FACS, Royal, Elective surgery, Coronary artery disease, Medicine, Mentorship, General surgery, Lung cancer, Ohio State University, Quality of life, Royal college, Georgia Tech, American College, Intellectual property, Ventricular septal defect, McLaren Health Care Corporation, Parent, Doctor of Philosophy, Multiple, Education, Mitral valve, Lung, MBBS, Physician

Divyakant B. Gandhi is an international physician, innovative thinker, and leader in cardiac care.

Key Points: 
  • Divyakant B. Gandhi is an international physician, innovative thinker, and leader in cardiac care.
  • He has been in practice as a Heart, Lung & Vascular surgeon for over 35 years.
  • As a leader in the clinical setting, Dr. Gandhi is the Chief of Staff, Medical Director, and Chief of Cardiovascular & Thoracic Surgery at McLaren Greater Lansing.
  • Dr. Gandhi practices his specialty under the auspices of the Center for Cardiovascular and Thoracic Surgery in Detroit, MI.

Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries

Retrieved on: 
Thursday, January 11, 2024
Artificial intelligence, Development, ASPR, Patient, Burn, MDAI, Policy, Knowledge, Foot, FACS, Administration, NASD, HHS, FDA, Clinical trial, Wound healing, Physician

DALLAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASD:MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, announces the enrollment of the first patient in the pivotal study to validate DeepView AI® using its proprietary imaging technology for burn size and healing assessment.

Key Points: 
  • DALLAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASD:MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, announces the enrollment of the first patient in the pivotal study to validate DeepView AI® using its proprietary imaging technology for burn size and healing assessment.
  • This pivotal study is expected to be the final clinical trial before seeking FDA marketing authorization for the burn indication in 2025 and will be conducted in burn centers and emergency departments across the US, enrolling both adults and pediatric patients.
  • The study will help us validate DeepView’s game-changing AI to accurately assess burn wound healing potential on day-one which could lead to early treatment decisions,” said Jeffrey C. Carter, MD, FACS, the lead investigator for the study.
  • The findings and conclusions have not been formally disseminated by HHS and should not be construed to represent any agency determination or policy.

American Urological Association Announces 2024 Innovation Nexus Showcase Selections

Retrieved on: 
Wednesday, January 10, 2024
Nexus, Woman, Patient, Fertility, American Urological Association, Trauma, Therapy, Prostate cancer, Artificial intelligence, Bladder cancer, Urology, Showcase, Cystoscopy, Funding of science, FACS, University, Surgery, Incontinence, Carboxypeptidase, Hyperoxaluria, Conference, Urinary tract infection, Information technology, Urethra, Patient safety, AUA, Medical imaging

Baltimore, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to announce the ten companies chosen through a rigorous and highly competitive selection process for the second annual Innovation Nexus Showcase.

Key Points: 
  • Baltimore, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to announce the ten companies chosen through a rigorous and highly competitive selection process for the second annual Innovation Nexus Showcase.
  • Innovation Nexus is a long-term commitment by the AUA to sustain a urology incubator to advance discoveries with key stakeholders to benefit urologic patient care.
  • As part of the multi-faceted program, the AUA will host an annual Innovation Nexus Conference, with the second event being held on May 2 in San Antonio, TX, before the AUA Annual Meeting.
  • For more information on the Showcase and to register to attend the May 2 event, please visit: https://auanexus.org/

HPC International Inc. Announces Partnership with St. Luke’s in Duluth, MN

Retrieved on: 
Tuesday, January 9, 2024
Research, Evidence-based practice, Hospital, Library, FACS, Regional Cancer Centre, Education, Nursing, American College, NIH, HPC, CME, Health, National Network, Retirement

A 2009 study by NIH reveals a medical librarian leads to improved clinical decision-making, which leads to improved patient outcomes.

Key Points: 
  • A 2009 study by NIH reveals a medical librarian leads to improved clinical decision-making, which leads to improved patient outcomes.
  • “We are thrilled to be working with such a great organization as St. Luke’s,” said Dr. Hilton Hudson, MD, FACS, CEO of HPC International.
  • Luke’s depends on virtual library support from HPC International,” said Eric Barto, St. Luke’s Director of Education & Patient Care Services.
  • “With the retirement of our librarian, HPC provided a seamless transition of service to our leadership and clinical teams.